The earnings call was largely positive, with GeneDx achieving record revenue and significant growth in exome and genome testing. The company improved its reimbursement rates and expanded into new markets. Although there are challenges related to new indications and the slower adoption of testing in general pediatrics, the overall outlook remains strong with raised revenue guidance and sustained profitability.

Company Guidance -

Q3 2025

During GeneDx's second quarter 2025 earnings call, the company provided updated guidance metrics and highlighted key achievements. GeneDx reported a record revenue of $102.7 million, marking a 49% year-over-year increase, with $85.9 million coming from exome and genome testing, which grew 69% from the same quarter last year. The average reimbursement rate for these tests increased to over $3,700, up from approximately $3,400 last quarter. GeneDx expects full-year revenue to be between $400 million and $415 million, raising exome and genome revenue guidance to deliver 48% to 52% growth. The company anticipates at least 30% year-over-year volume growth and has raised its full-year adjusted gross margin expectations to between 68% and 71%. GeneDx also affirmed its commitment to remain profitable each quarter on an adjusted net income basis for 2025. The call emphasized GeneDx's strategic initiatives, including expanding into new indications, leveraging their extensive genomic data set, and integrating Fabric Genomics to enhance their platform capabilities.

Record Revenue Achievement

GeneDx delivered over $100 million in revenue for the first time in a single quarter, with total second quarter 2025 revenues reaching $102.7 million, a 49% increase year-over-year.

Exome and Genome Revenue Growth

Revenue from exome and genome tests hit a record high of $85.9 million, up 69% from the same quarter last year.

Increased Average Reimbursement Rate

Average reimbursement rate for exome and genome tests increased to over $3,700 per test, up from approximately $3,400 last quarter.

Expanded Market Opportunities

Increased engagement with pediatric neurologists and immunologists and expansion into the NICU market, which represents a $1 billion opportunity.

Improved Gross Margin

Total company adjusted gross margin expanded to a record high of 71%, driven by a favorable mix shift, improved reimbursement, and lower COGS.

Sustained Profitability

GeneDx reported $15 million in adjusted net income, marking the fourth consecutive quarter of profitability.

Raised Revenue Guidance

Full year 2025 total revenue guidance raised to between $400 million and $415 million, with exome and genome revenue expected to grow between 48% and 52%.

GeneDx Holdings (WGS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

WGS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	0.36 / -	0.04	―	―	―
Jul 29, 2025	2025 (Q2)	0.12 / 0.50	-0.107	567.29% (+0.61)
Apr 30, 2025	2025 (Q1)	0.06 / 0.28	-0.33	183.33% (+0.60)
Feb 18, 2025	2024 (Q4)	0.16 / 0.77	-0.491	257.03% (+1.26)
Oct 29, 2024	2024 (Q3)	-0.21 / 0.04	-0.821	104.87% (+0.86)
Jul 30, 2024	2024 (Q2)	-0.30 / -0.11	-1.648	93.51% (+1.54)
Apr 29, 2024	2024 (Q1)	-0.67 / -0.33	-2.437	86.46% (+2.11)
Feb 20, 2024	2023 (Q4)	-0.65 / -0.49	-29.7	98.35% (+29.21)
Oct 30, 2023	2023 (Q3)	-1.31 / -0.82	-6.655	87.66% (+5.83)
Aug 08, 2023	2023 (Q2)	-1.31 / -1.65	-7.126	76.87% (+5.48)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

WGS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$84.91	$91.78	+8.09%
Apr 30, 2025	$116.97	$66.85	-42.85%
Feb 18, 2025	$76.35	$112.76	+47.69%
Oct 29, 2024	$56.06	$84.02	+49.88%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Genedx Holdings Corp. (WGS) report earnings?

Genedx Holdings Corp. (WGS) is schdueled to report earning on Nov 17, 2025, After Close (Confirmed).

What is Genedx Holdings Corp. (WGS) earnings time?

Genedx Holdings Corp. (WGS) earnings time is at Nov 17, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is WGS EPS forecast?

WGS EPS forecast for the fiscal quarter 2025 (Q3) is 0.36.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing